Announced Positive Topline Data from OPUS-1 Pivotal Phase 3 Trial; VAX-31 Met All Prespecified Primary Endpoints, Was Well ...
ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness. ANN ARBOR, MI / ACCESS Newswire / November 4, 2026 / ...
Achieved $45.0 million in third quarter 2026 total revenue, including $27.5 million in net product revenue for IBTROZI® ...
Effective at the commencement of trading on November 5, 2026, the Common Shares are expected to begin trading on The Nasdaq ...
Donlin Gold Holdings, 100% wholly-owned by Paulson Advisers LLC and its affiliates, is the 40% owner of the Donlin Gold ...
First nine months 2026 net earnings (1) of $1.78 billion, or $11.60 per diluted share, EBITDA (2) of $3.00 billion, and adjusted EBITDA (2) of $3.01 billion. First nine months 202 ...
BillionToOne now expects full year 2026 total revenue of $460.0 million to $470.0 million, representing growth of 51% to 54% compared to full year 2025. This compares to the company's previous ...
Vir Biotechnology will host its third quarter 2026 financial results conference call at 4:30 p.m. ET / 1:30 p.m. PT today. A ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results